Literature DB >> 27109265

Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics.

John F Timms1, Oliver J Hale2, Rainer Cramer2.   

Abstract

INTRODUCTION: The last 20 years have seen significant improvements in the analytical capabilities of biological mass spectrometry (MS). Studies using advanced MS have resulted in new insights into cell biology and the etiology of diseases as well as its use in clinical applications. AREAS COVERED: This review discusses recent developments in MS-based technologies and their cancer-related applications with a focus on proteomics. It also discusses the issues around translating the research findings to the clinic and provides an outline of where the field is moving. Expert commentary: Proteomics has been problematic to adapt for the clinical setting. However, MS-based techniques continue to demonstrate potential in novel clinical uses beyond classical cancer proteomics.

Entities:  

Keywords:  MALDI; Mass spectrometry; REIMS; biotyping; cancer proteomics; cancer research; clinical diagnostics; clinical mass spectrometry; mass spectrometry imaging; pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 27109265     DOI: 10.1080/14789450.2016.1182431

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  5 in total

1.  Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet's Disease.

Authors:  Hyun Jung Lee; Jae Hyun Kim; Seung Won Kim; Hyun Ah Joo; Hye Won Lee; You Sun Kim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Young-Ho Kim; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

2.  CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells.

Authors:  Yiyi Pu; Dongmei Yan; Linglan Tu; Liyan Cheng; Jie Yu; Zhuduo Li; Xiaoliang Zheng; Xinbao Wang
Journal:  Dis Markers       Date:  2022-03-11       Impact factor: 3.434

3.  Affinity Proteomics Exploration of Melanoma Identifies Proteins in Serum with Associations to T-Stage and Recurrence.

Authors:  Sanna Byström; Claudia Fredolini; Per-Henrik Edqvist; Etienne-Nicholas Nyaiesh; Kimi Drobin; Mathias Uhlén; Michael Bergqvist; Fredrik Pontén; Jochen M Schwenk
Journal:  Transl Oncol       Date:  2017-04-20       Impact factor: 4.243

4.  Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics.

Authors:  Xiaoying Ye; Brian T Luke; Bih-Rong Wei; Jan A Kaczmarczyk; Jadranka Loncarek; Jennifer E Dwyer; Donald J Johann; Richard G Saul; Dwight V Nissley; Frank McCormick; Gordon R Whiteley; Josip Blonder
Journal:  Oncotarget       Date:  2018-05-29

Review 5.  Challenging the heterogeneity of disease presentation in malignant melanoma-impact on patient treatment.

Authors:  A Marcell Szasz; Johan Malm; Melinda Rezeli; Yutaka Sugihara; Lazaro H Betancourt; Daniel Rivas; Balázs Gyorffy; György Marko-Varga
Journal:  Cell Biol Toxicol       Date:  2018-10-24       Impact factor: 6.691

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.